Rating Change
HC Wainwright & Co. reiterated its Buy rating on Tango Therapeutics, Inc. (NASDAQ:TNGX) on August 18, 2026.
reiterateNASDAQ:TNGX
HC Wainwright & Co. Reiterates Buy Rating on Tango Therapeutics, Inc. (TNGX)
HC Wainwright & Co. reiterated its Buy rating on Tango Therapeutics, Inc.
At publication ·
What changed
Tango Therapeutics, Inc. (NASDAQ:TNGX) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $25.44
- Market capitalization
- $1.0B
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Tango Therapeutics (TNGX) on August 18, 2026, with the stock trading at $25.44 and a market capitalization of $1.0 billion.
Market Context
Tango Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $25.44 with a market capitalization of $1.0B. The stock has gained 265.5% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Tango Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Tango Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 12, 2026 | Guggenheim | Buy | N/A |
| Jul 17, 2026 | Mizuho | Outperform | N/A |
| Jul 15, 2026 | JP Morgan | Overweight | N/A |
| Jun 29, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View TNGX Stock Page
Frequently Asked Questions
What does the Buy rating mean for TNGX?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Tango Therapeutics, Inc. (NASDAQ:TNGX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TNGX forecast page.